Canta Hyperbaric Chamber Global Commercialisation Strategy and Partnership Forum

In July 2026, the "Canta Hyperbaric Oxygen Chambers Global Commercialization Strategy and Partnership Forum" was successfully held. The forum brought together industry experts and representatives from Canta's partners for in-depth discussions on scientific research achievements, application pathways, and commercial development in the field of hyperbaric oxygen therapy for anti-aging.

Research on Anti-Aging Effects of HBOT Receives Authoritative Recognition

At the forum, Canta unveiled its latest research achievements in hyperbaric oxygen therapy (HBOT) for anti-aging. This experiment completed a large-scale, multi-dimensional human study on the anti-aging effects of hyperbaric oxygen therapy, providing empirical evidence of its significant anti-aging benefits across three core biomarkers: telomere length, senescent T cells, and inflammatory cytokines. An expert review panel comprising leading specialists from the National Health Commission of China, Peking University, China Medical University, and other authoritative institutions, conducted a rigorous scientific evaluation of Canta's research findings on hyperbaric oxygen therapy for anti-aging and unanimously concluded that the project has passed the review!

In its comprehensive review, the expert panel noted that the project is at the forefront of aging intervention research and aligns with the development trends of both anti-aging medicine and hyperbaric medicine. The panel concluded that the research design, technical approach, and the entire process comply with medical research standards; the data and conclusions are objective and reasonable; and the overall research has reached an internationally advanced level. It holds broad prospects for market application, and it will help advance anti-aging research and health promotion.

Building upon this scientific foundation, Canta has further established the technical principles and product standards required for effective hyperbaric oxygen anti-aging therapy. A hyperbaric oxygen chamber that truly possesses clinical biological effects must simultaneously meet two essential requirements: 'high pressure' and 'BIBS'. Pressure provides the physical basis for oxygen to penetrate deep tissues, whilst the breathing system directly determines the concentration of oxygen actually inhaled by the user. Canta's hyperbaric oxygen chambers utilise a sealed oxygen mask combined with dual independent inhalation and exhalation circuits, enabling users to inhale oxygen at concentrations exceeding 95%, whilst exhaled gas is discharged directly outside the chamber. Operating at a therapeutic pressure of 2.0 ATA and equipped with a medical-grade BIBS solution, the system ensures the effectiveness of oxygen therapy. Today, Canta's hyperbaric chambers have been successfully deployed in premium wellness centres, commercial spaces, sports recovery centres, and other high-end healthcare environments.

Scientific Discussions to Foster a New Industry Ecosystem

During the panel discussion, leading experts engaged in an in-depth exchange on the practical applications, standardisation, and clinical value of hyperbaric oxygen therapy. They unanimously agreed that hyperbaric oxygen therapy spans proactive prevention, clinical rehabilitation, and daily care, serving as an effective early intervention to enhance quality of life and promote healthier longevity. As the applications of hyperbaric oxygen continue to expand, manufacturers need to refine their diversified range of hyperbaric chambers to cover diverse settings such as clinical treatment, sports rehabilitation, commercial wellness facilities, and home healthcare, thereby comprehensively meeting the public's health management needs throughout their entire life cycle.

During the Q&A session, one attendee pointed out that low-cost, low-pressure hyperbaric chambers are currently entering the market, and asked how Canta intends to respond to this competition whilst maintaining its commitment to medical-grade quality, and whether Canta plans to introduce a 'lightweight' product line. Canta responded unequivocally that it will not compromise product standards to compete on price. The company's commitment to 2.0 ATA hyperbaric oxygen chambers is firmly supported by scientific research and clinical evidence. In contrast, the effectiveness of the low-pressure oxygen chambers currently available on the market remains unproven by medical evidence. Looking ahead, Canta will continue to conduct research into the relationship between pressure and therapeutic outcomes, and calls on other hyperbaric chamber manufacturers to actively participate, believing that robust scientific validation is essential to advancing the industry and establishing a stronger foundation for long-term innovation and sustainable development.

Intelligent Manufacturing Tour Showcasing Canta's Capabilities

Canta also invited the guests to visit its Precision Manufacturing Industrial Plant. Participants gained an in-depth insight into Canta's production lines and spoke highly of the company's outstanding capabilities in independent research and development, production, quality control systems, and production capacity assurance. Some attendees also experienced Canta's hyperbaric chambers first-hand, expressing strong recognition of the chambers' user-friendly design, safety control systems, and comfort.

The successful hosting of this forum highlights Canta's technological expertise, manufacturing excellence, and global vision in the field of hyperbaric oxygen chambers, and further signifies that the hyperbaric oxygen anti-aging industry is moving from proof of concept to a new phase of large-scale development. Looking ahead, Canta will continue to drive product innovation through scientific research, advancing the integration of hyperbaric oxygen technology and longevity medicine. Canta is committed to working hand in hand with partners to build a new, comprehensive health ecosystem.